BRIEF-Johnson & Johnson Unveils First-In-Human Results For Pasritamig, Showing Early Anti-Tumor Activity In Prostate Cancer

Reuters
01 Jun
BRIEF-Johnson & Johnson Unveils First-In-Human Results For Pasritamig, Showing Early Anti-Tumor Activity In Prostate Cancer

June 1 (Reuters) - Johnson & Johnson JNJ.N:

  • JOHNSON & JOHNSON UNVEILS FIRST-IN-HUMAN RESULTS FOR PASRITAMIG, SHOWING EARLY ANTI-TUMOR ACTIVITY IN PROSTATE CANCER

  • JOHNSON & JOHNSON - PASRITAMIG SHOWS POTENTIAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

  • JOHNSON & JOHNSON - DATA SHOW LOW RATES OF TREATMENT-RELATED ADVERSE EVENTS

Source text: ID:nPn7LpmPka

Further company coverage: JNJ.N

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10